CMED Group joins AIXIAL


AIXIAL has announced the acquisition of UK headquartered CMED Group by ALTEN EUROPE. CMED is a technology led CRO that specializes in full-service oncology, immuno-oncology, cell therapy and rare diseases, and provision of data and analytic services. CMED also has a technology division that is the developer of encapsia, a clinical data suite purpose designed to support traditional, decentral, virtual and hybrid clinical trials.

AIXIAL Group continues to build a global presence in size and scale with over 1,000 employees across the United States and Europe.

For more information, click here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.